<DOC>
	<DOCNO>NCT02542514</DOCNO>
	<brief_summary>The study open label , prospective , multicenter , phase II study aim define ibrutinib efficacy patient relapse refractory primary central nervous lymphoma ( PCNSL ) intraocular lymphoma ( IOL ) measure disease control ( DC ) rate ( complete response ( CR ) + uncertain complete response ( Ru ) + partial response ( PR ) stabilize disease ( SD ) ) 2 cycle treatment accord International study group PCNSL ( IPCG ) criterion .</brief_summary>
	<brief_title>Study Ibrutinib Patients With Relapsed Refractory Primary Central Nervous Lymphoma Intraocular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<criteria>1 . Histologically confirm diagnosis PCNSL cytologically proven diagnosis IOL lymphomatous meningitis Bcell type . In case CNS lymphoma relapse refractory PCNSL , cerebral biopsy require imaging reveals typical image PCNSL . In case isolate IOL relapse , vitrectomy require ) vitrectomy part initial diagnosis workout , ii ) ocular examination dosage IL10 anterior chamber eye perform relapse progression highly favour IOL relapse ( &gt; 50 pg/ml aqueous humor 400 pg/ml vitreous ) . 2 . Aged 18 year old . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 . 4 . Life expectancy ≥ 3 month . 5 . No 4 line anticancer treatment receive . 6 . Patients must recover within 28 day grade ≤ 1 toxicity relate prior treatment . 7 . Adequate Laboratory Parameters within 14 day : 8 . Measurable PCNSL diagnose MRI 9 . Highly effective method birth control study consistent . Men must agree donate sperm study . These restriction apply 1 year last dose study drug . 10 . Women childbearing potential must negative serum betahCG urine pregnancy test Screening . 11 . Sign inform consent document.The inform consent document sign person confidence case neurologic disorder related disease prevent patient sign . 1 . Contraindication excipients drug . 2 . Tcell lymphoma . 3 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) , prior history systemic lymphoma , unless patient free disease ≥ 3 year . 4 . Prior history organ transplantation cause severe immunodeficiency . 5 . Major surgery , within 4 week prior first dose study drug . 6 . History stroke intracranial hemorrhage within 6 month prior randomization . Patients postbiopsies hemorrhagic sequela define small hyperdense lesion &lt; 3 mm T2* sequence wo n't exclude . 7 . Requires anticoagulation warfarin equivalent vitamin K antagonists ongoing warfarin medication equivalent vitamin K antagonists . 8 . Any antiplatelet aggregant medication except acetyl salicylic acid ≤ 75 mg/day . 9 . Requires treatment strong CYP3A4 inhibitor . 10 . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month Screening , Class 3 Class 4 cardiac disease define New York Heart Association Functional Classification . 11 . Vaccinated live , attenuated vaccine within 4 week prior first dose study drug . 12 . Known history HIV active Hepatitis C Virus ( HCV ; RNA polymerase chain reaction [ PCR ] positive ) active Hepatitis B Virus ( HBs Ag positive DNA PCRpositive ) infection uncontrolled active systemic infection require intravenous ( IV ) antibiotic . 13 . Any lifethreatening illness , medical condition , organ system dysfunction could compromise subject 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk . 14 . Inability swallow capsule . 15 . Pregnancy lactation . 16 . Use anticancer drug therapy within 21 day prior first dose study drug . 17 . Previous treatment BTK inhibitor PI3K inhibitor . 18 . Known bleeding diathesis . 19 . Inclusion another experimental anticancer drug therapy* . 20 . Assessed investigator unable unwilling comply requirement protocol . 21 . Patient measure legal protection . 22 . No social security affiliation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PCNSL</keyword>
	<keyword>IOL</keyword>
</DOC>